Current Reviews in Clinical and Experimental Pharmacology is a cutting-edge journal published by Bentham Science Publishers in the United Arab Emirates, focusing on the dynamic field of pharmacology. With an ISSN of 2772-4328 and an E-ISSN of 2772-4336, this journal has rapidly established itself as a significant resource for researchers and professionals in the medical and pharmaceutical sciences since its inception in 2021. It boasts an impressive Q3 ranking in Pharmacology (medical) and Q2 in the Pharmacology, Toxicology and Pharmaceutics (miscellaneous) category as of 2023. Furthermore, it ranks #14/80 in general pharmacology, reflecting its esteemed position within the scientific community. As an Open Access publication, it ensures that groundbreaking research is readily accessible, fostering collaboration and innovation. The journal invites high-quality reviews and original articles that address contemporary issues and advancements in clinical and experimental pharmacology, making it an essential venue for disseminating knowledge and engaging with emerging trends in therapeutic developments.

US PHARMACIST, published by Jobson Publishing LLC, is a key resource in the field of pharmaceutical sciences and pharmacy, with a robust legacy dating back to 1979. The journal, identifiable by the ISSN 0148-4818 and E-ISSN 2331-3501, serves as a platform for sharing insightful research, critical reviews, and advancements that shape the industry and improve patient care. Although categorized in the fourth quartile for several aspects of pharmaceutical science and pharmacology, its targeted focus on pharmacy practice provides a unique perspective that is essential for practitioners and students alike. The journal offers an essential medium for continuous professional development, promoting knowledge dissemination among healthcare professionals. Given its dedication to enhancing pharmaceutical education and practice, it remains a vital tool for those engaged in the science and application of pharmacy. Notably, access options are not open, but subscribers can benefit from the journal's rich content focused on advancing the pharmacy field in the context of contemporary health challenges.

CURRENT MEDICAL RESEARCH AND OPINION, published by Taylor & Francis Ltd, is a distinguished journal that has been at the forefront of medical research since its inception in 1972. With a vested interest in advancing healthcare knowledge, this journal encompasses a wide array of disciplines within the medical field, categorizing itself in Q2 of the Medicine (Miscellaneous) category according to the 2023 rankings. Notably, it holds a commendable rank of #119 out of 636 in the General Medicine category on Scopus, indicating its relevance and influence within the medical community, supported by an 81st percentile ranking. Although it does not present Open Access options, the comprehensive research articles, systematic reviews, and expert opinions it publishes are crucial for researchers, clinicians, and students who seek to deepen their understanding and drive innovations in medical practice. With its commitment to high-quality and impactful scientific communication, CURRENT MEDICAL RESEARCH AND OPINION remains an essential resource for those dedicated to advancing healthcare and improving patient outcomes.

Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.

EXPERT OPINION ON BIOLOGICAL THERAPY, published by Taylor & Francis Ltd, is a prestigious journal that has been a cornerstone in the fields of Clinical Biochemistry, Drug Discovery, and Pharmacology since its inception in 2001. With an impressive impact factor reflecting Q1 status across its categories in 2023, this journal is ranked among the top in both the pharmacology and biochemistry domains, featuring in the 81st and 77th percentiles respectively. This makes it an essential resource for researchers, professionals, and students who are keen on staying at the forefront of biological therapy advancements. The journal encompasses a broad yet focused scope, providing valuable insights into innovative therapeutic strategies and drug development methodologies. Researchers benefit from the rigorous peer-review process and the opportunity to disseminate their findings to a global audience, without the constraints of open access, ensuring the integrity and prestige of published work. As it converges towards 2024, EXPERT OPINION ON BIOLOGICAL THERAPY remains an influential platform for fostering collaboration and discussion in the evolutionary landscape of biological therapies.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, published by SAGE PUBLICATIONS LTD, is a pivotal resource in the fields of oncology, pharmacology, and medicine, with a dedicated focus on the evolving discipline of oncology pharmacy. Based in the United Kingdom, this journal has been diligently serving its readers since 1995 and continues to explore the intersection of pharmaceutical care and cancer treatment, showcasing innovative practices, research findings, and clinical advancements that are indispensable for healthcare professionals, researchers, and students alike. Although not an open-access journal, it holds a respectable Category Quartile Q3 ranking across its various fields, including Medicine, Oncology, and Pharmacology, indicating its relevance in nurturing academic discourse and addressing critical issues in cancer care. With an ISSN of 1078-1552 and E-ISSN of 1477-092X, the journal invites contributions that enhance the understanding of pharmaceutical interventions in oncology, aiming to improve therapeutic outcomes and patient care. Join a global community of professionals committed to excellence in oncology pharmacy practice and stay informed with cutting-edge research and reviews that significantly impact patient healthcare strategies.

EXPERT OPINION ON EMERGING DRUGS, published by Taylor & Francis Ltd, stands at the forefront of the pharmacological sciences, focusing on the rapid development and evaluation of innovative therapeutic agents. With an impressive impact factor that reflects its contributions to the field, this journal is indexed under ISSN 1472-8214 and E-ISSN 1744-7623. The journal has consistently attained high recognition, currently holding a Q2 ranking in Pharmacology and a Q1 ranking in Pharmacology (medical) as of 2023, which places it within the top tiers of scholarly publications. Covering a broad range of topics related to emerging pharmaceuticals, it aims to bridge the gap between research and clinical practice by providing critical reviews, expert opinions, and insightful analyses. Based in the United Kingdom and actively published since 2000, the journal seeks to inform and inspire researchers, professionals, and students alike, offering a platform to foster collaboration and insight within the ever-evolving domain of drug development and pharmacotherapy.

Expert Opinion on Investigational Drugs, published by Taylor & Francis Ltd, is a premier journal dedicated to the dissemination of high-quality, peer-reviewed research in the fields of pharmacology and medicine. As an integral part of the scientific community since its inception in 1994, this journal has established itself as a leading source of insightful analysis and expert commentary on emerging drug therapies, providing invaluable resources for researchers, clinicians, and healthcare professionals. With an impressive impact factor and ranking in the top quartile across multiple pharmacological categories, it remains a vital platform for discussing innovative drug developments and their clinical applications. Though it operates on a subscription basis, Expert Opinion on Investigational Drugs is crucial for anyone involved in pharmacological research and the drug development process, positioning itself at the forefront of medical advancements and offering critical insights into the rapid evolution of investigational therapies.

Pain Management, published by Future Medicine Ltd, is a premier journal that serves the fields of anesthesiology, pain medicine, and dentistry. With its ISSN 1758-1869 and E-ISSN 1758-1877, this journal is committed to advancing knowledge and practice through high-quality research articles, clinical studies, and expert reviews. The journal has established itself as a pivotal resource in pain management with a commendable impact factor and recognition in category quartiles, achieving Q2 rankings in Anesthesiology and Pain Medicine, as well as in miscellaneous Medicine and Dentistry categories as of 2023. Researchers and professionals will find a wealth of information in its comprehensive articles, which are essential for staying at the forefront of developments in pain management therapies and techniques. Although access is not open, the journal is recognized for its rigor and significance in shaping the future of pain management practices globally. Join the community of experts engaging in cutting-edge discussions by exploring the impactful research being published in this essential resource.

Rational Pharmacotherapy in Cardiology, published by the SOC CARDIOLOGY RUSSIAN FEDERATION, stands as a crucial platform for advancing knowledge in the field of cardiology and pharmacology. Established as an Open Access journal in 2005, it allows for unrestricted access to research findings, fostering collaboration among researchers, clinicians, and students. The journal, with its ISSN 1819-6446 and E-ISSN 2225-3653, focuses on the intersection of rational pharmacotherapy and cardiovascular medicine, aiming to enhance treatment strategies and patient outcomes through evidence-based studies. Though currently positioned in the Q4 category in both cardiology and pharmacology rankings, its ongoing commitment to rigorous peer review and scholarly research ensures its relevance and growth in the scientific community. With a unique address in Moscow, Russia, the journal seeks to serve as a valuable resource for those dedicated to improving cardiovascular health and therapeutic practices worldwide, making it an essential read for professionals keen on the latest trends and discoveries in this vital area of medicine.